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Abstract
Background Detrusor overactivity (DO) is one of the
most frequent bladder dysfunctions in children up to the
age of 18. Nowadays, the only way to confirm DO is by
urodynamic investigation, which is an invasive procedure.
Among the many mediators influencing bladder function,
nerve growth factor (NGF) plays an important role. The
present study was designed to measure urinary NGF
(uNGF) levels in patients with DO diagnosed by urody-
namic study in comparison with healthy controls.
Methods The investigation was conducted on 44 children,
divided into two groups (24 patients with DO, 20 healthy
children). Uroflowmetry was performed in all enrolled to
the study and cystometry only to patients. uNGF levels
were estimated in both studied groups.
Results The median uNGF level in patients with DO
before treatment was higher compared with healthy con-
trols. There were no differences between uNGF levels in
patients after anticholinergic treatment and the controls.
We found differences in uroflowmetry parameters between
the reference group and the patients. We found correlations
between uroflowmetry parameters and uNGF/cr. level.
Conclusions
1. The uNGF level could be used for detecting DO in
children and adolescents.
2. Measuring uNGF level is a simple, noninvasive
procedure and very useful for choosing therapy in
patients with DO in various clinical conditions.
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Introduction
Many factors are involved in bladder function, such as
prostanoids, ATP, NO, cytokines, immunoglobulins, free
oxygen radicals, nerve growth factor and physicians make
several attempts to help affected patients [1]. Detrusor
overactivity (DO) is the most common bladder dysfunction
in children and adolescents and plays an important role in
reoccurring symptoms such as: urgency, frequency with or
without urinary incontinence [2]. Detrusor overactivity
(DO) can complicate vesicoureteral refluxes (VURs) [3]
and causes nocturnal enuresis (NE) [4]. Until now, uro-
dynamics, an invasive procedure, was the only method for
confirming DO. In recent studies, many authors focused on
the role of NGF level with pathogenesis of DO [5–7].
NGF, which belongs to the neurotrophin group, is
responsible for the growth and maintenance of sympathetic
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and sensory neurons. It plays an important role in auto-
nomic innervations of many organs [8, 9]. Neurotransmit-
ters, such as NGF, provide mechanisms for bidirectional
communication between muscle or urothelium and nerve,
leading to OAB with or without urge incontinence [9].
NGF might regulate neural function of both sensory and
motor neurons [10]. Most studies concerned with NGF
activity were conducted on adult populations or on animal
models [5, 6, 11–13]. Changes in urine NGF levels in adult
patients with DO were also observed by Kim et al. [14],
Liu et al. [11, 15–17] and Kuo [18]. To the best of our
knowledge, there is only one study in the pediatric popu-
lation estimating NGF in children with OAB, however, in
this study DO was not confirmed by urodynamic investi-
gation in all patients [19]. Hence, we decided to assess the
role of NGF in the pathogenesis of DO in children and
adolescents.
The present study was designed to measure urinary NGF
(uNGF) levels in patients with DO confirmed by urody-
namic investigation and to compare these levels with
healthy controls and before and during anticholinergic
treatment. This study may answer the question whether
NGF could be a biomarker of detrusor overactivity in
children and adolescents.
Methods
The investigation was conducted on 44 children, divided
into two groups. The patient group included 24 children
aged median 8.25 years (1.5–17). All of these children
were diagnosed with DO based on urodynamic investiga-
tion. All of them were under the care of Department of
Pediatrics and Nephrology and Outpatient Nephrological
Clinic. The patients were examined twice: A—at the
moment of DO diagnosis by urodynamic procedure (cys-
tometry and uroflowmetry were performed and the first
urine sample was obtained) and B—after 4–6 weeks of
anticholinergic treatment (only uroflowmetry was per-
formed and a second urine sample was obtained). The
control group consisted of 20 healthy children aged median
11 years (3–17) with no abnormalities in urinary and ner-
vous systems recruited to the study as children-volunteers
of hospital staff.
Inclusion criteria: (1) patients: aged 1–18 years with DO
in urodynamics, (2) uroflowmetry was performed in all
children and cystometry was performed in patients, (3)
oxybutynin treatment for 4–6 weeks after DO was diag-
nosed based on cystometry.
Exclusion criteria: (1) UTI in the last 2 months, (2)
presence of other infections, (3) abnormalities in urinary
tract or/and nervous system.
The biochemical work-up included: serum and urine
creatinine (measured by Jaffe reaction); urea; and glo-
merular filtration rate (ml/min/1.73 m2) estimated by the
Schwartz formula (eGFR): GFR = k 9 H (cm)/Lcr (mg/
dl), where k––age-dependent coefficient (0.55 in boys
under 12 years and girls at any age, 0.7 in boys over
12 years), H—high, Lcr—level of creatinine in serum.
The urodynamic work-up included: uroflowmetry
parameters: (1) time to max flow, (2) flow and voiding
time, (3) maximum and average flow rate, (4) voided
volume, (5) residual urine (calculated by USG immediately
after micturition); mean values of three measurements were
analyzed; in cystometry: (1) detrusor pressure at urgency
(Pdet urg), (2) bladder wall compliance (comp), (3) cys-
tometric capacity (CC), 4. maximum detrusor pressure on
voiding phase (max p det). Urodynamic investigations
were performed after typical preparation of patients
according to the ICCS rules.
In examination A the urine samples were collected
during uroflowmetry before the urodynamic procedure. In
examination B and reference group the samples were
obtained from morning urine before control uroflowmetry.
Urinary tract infections were excluded based on normal
urinalysis and urine culture tests. A negative C-reactive
protein (CRP) result excluded current infection.
The urine samples were taken to measure the urinary
NGF (uNGF) level. Daily urine samples were frozen
directly after spinning. Samples were stored in a temper-
ature of -80 C. Written informed consent was obtained
from all enrolled subjects, subsequent to receiving full
information about the study.
The uNGF levels were measured using the ELISA set
(enzyme-linked immunosorbent assay). The Emax Immu-
noassay System (Promega, Madison, WI, USA) was used
to confirm the concentration of urine NGF in both groups
of children. The investigation was executed according to
the manual instructions. Total uNGF levels were stan-
dardized to mg of creatinine and the results were expressed
as a NGF/creatinine ratio (pg/mgcreatinine)(NGF/cr.).
Data analysis was performed using Statistica ver. 10.0
(StatSoft Inc., Tulsa, OK, USA). Normal distribution of
data was tested with the Shapiro–Wilk W test and then
statistical analysis was performed using non-parametric
tests. For comparison between groups the Mann–Whitney
test was used as well as the Wilcoxon and Chi square test
for intra group comparisons. The Spearman test was used
to assess correlations among the studied parameters. A
p value of less than 0.05 was considered statistically
significant.
The study was approved by the Ethics Committee of the
Medical University of Bialystok in accordance with the
Declaration of Helsinki.
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Results
The patients’ clinical characteristics are presented in
Table 1. There were no differences in the age (p = 0.06),
weight (p = 0.07), height (p = 0.1) or gender (p = 0.7)
between the patients and the reference group.
Additionally, we analyzed kidney function parameters.
The results are shown in Table 1. We did not find any
statistically significant difference in the serum and urine
median creatinine concentrations nor in GFR. Urine
osmolality was similar in the study and the reference
group.
In the DO group, abnormalities in ultrasound examina-
tions were observed in 8/24 (33 %) patients. The most
frequent changes were: bladder wall thickening in 6/24
(25 %), loss of cortex/medullae differentiation in 2/24
(8.3 %). No statistically significant differences in urinary
NGF/cr. level between children with and without ultra-
sound abnormalities were found before treatment [82.3
(3.1–223), 51.1 (3.1–239.1), respectively; p = 0.7] and
after treatment [3.3 (0.9–6.4); 5.6 (3.8–8.5), respectively;
p = 0.6].
LUTSs were observed in the majority of patients. The
most frequent abnormality was nonmonosymptomatic
enuresis. Recurrent UTIs in the DO group were found in
12/24 (50 %) patients. Detailed data are presented in
Table 2. Analysis of the clinical symptoms and urody-
namic findings in our patients revealed that OAB symp-
toms are not a reliable indicator of DO.
In further analysis, we assessed and compared uro-
flowmetry parameters in patients with DO (A and B) and
the controls. We found statistically significant differences
in most uroflowmetry parameters between the reference
group and the patients, both before as well as after
4–8 weeks of treatment. However, there were no differ-
ences in maximum flow rate and average flow rate between
the study and the reference group. Voided volume was
larger after treatment than before but still smaller when
compared with the reference group. There were no
differences in the amount of residual urine. In all groups,
values were in the normal range.
We evaluated Pdet urg [median 30 (7–63) cm H2O], CC
[median 109 (50–240) ml], comp [median 11.5 (0.6–27.8)
ml/cm H2O] and max p det [median 60 (11–149) cm H2O]
in the cystometry test. Cystometric capacity in the study
group before treatment was lower than expected for age.
Similarly, bladder wall compliance was lower than normal
values. All uroflowmetry and cystometry data are shown in
Table 3.
Further statistical analysis using multiple comparisons
between the groups revealed that the median value of
uNGF/cr. in DO patients before treatment was signifi-
cantly higher [median 65.8 (3.1–223)] when compared
with the reference group [median 5.7 (1.1–58.8)]
(p\ 0.01). After a few weeks of anticholinergic treat-
ment, uNGF/cr. decreased [median 6.1 (0.9–85.6)] and
did not differ from the reference group (p = 0.7). The
median value of uNGF level before treatment was sig-
nificantly higher than after a few weeks of treatment
(Wilcoxon test) (p\ 0.01) (Fig. 1). We did not find dif-
ferences in uNGF/cr. between patients with VURs and
urine incontinence (p = 0.7).
We found correlations between uroflowmetry parame-
ters and uNGF/cr. level. Delay time correlated positively
with uNGF/cr before treatment (R = 0.568; p\ 0.01).
UNGF/cr. levels correlated negatively with time to max
flow rate (R = -0.718; p\ 0.01), flow time (R = -0.627;
p\ 0.01), voiding time (R = -0.618; p\ 0.01), and
voided volume (R = -0.499; p\ 0.01). There were no
correlations between uNGF/cr. levels and maximum flow
rate (R = 0.132; p = 0.4) and average flow rate
(R = 0.118; p = 0.6).
Additionally, we found a positive correlation between
uNGF/cr. level and bladder wall compliance (R = 0.503;
p\ 0.01) before treatment, and a negative correlation
between uNGF/cr. level and maximum detrusor pressure
during voiding phase (R = -0.528; p\ 0.01) before
treatment.
Table 1 Characteristics of
studied patients (with DO),
healthy controls and comparison
between both groups
* p value\0.05
DO patients median (range) controls median (range) p value
Girls/boys 18/6 16/4 0.694
Age/years 8.25 (1.5–17) 11 (3–17) 0.06
Height 127.5 (77–160) 152 (100–169) 0.106
Body weight/kg 25.5 (12–64) 38.6 (12–68) 0.067
Urine osmolality 905 (752–1,058) 935 (780–1,120) 0.894
Serum creatinine (mg/dl) 0.43 (0.31–0.68) 0.52 (0.2–0.85) 0.051
GFR (ml/min/1.73 m2) 177.56 (129–210) 164.46 (110–330) 0.934
Urine creatinine (mg/dl) 103.51 (42.15–163.71) 106.99 (57.8–244.05) 0.122
Anticholinergic treatment (mg/kg/day) 0.2 (0.18–0.3)
Treatment time (weeks) 5.5 (4–8)
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We attempted to determine the cut-off value of uNGF/
cr. level for the prediction of DO using a ROC curve. This
analysis showed a cut-off value of[5.8 pg/mg cr. with a
sensitivity, specificity, positive predictive value, and neg-
ative predictive value of 93.5, 100, 100, and 95.5 %,
respectively. The area under the curve was 0.995, with a
95 % confidence interval (CI) of 0.982–1.0 (Fig. 2).
Discussion
Detection of DO is critical in the diagnostic process of
many urinary tract problems. DO can complicate vesico-
ureteral reflux (VUR) [3], can cause UTI [2] or nocturnal
enuresis (NE) [4]. Many LUTSs appear due to DO. In part,
patients with symptoms such as urgency or incontinence
have normal bladder function. Diagnosis of DO is usually
done using an invasive procedure, such as urodynamic
investigation. However, not all patients with symptoms of
OAB have urodynamically proven DO, and not all patients
with DO confirmed by urodynamics have clinical OAB
symptoms. Performing urodynamics is especially compli-
cated in children up to the age of 18. Young patients can
not understand why such an invasive procedure is being
used. On the other hand, children cannot express their
feelings exactly and the physician should confirm his sus-
picions through adequate tests. The situation is much more
complicated when the patient has urinary incontinence and
those symptoms might originate from urethral incompe-
tence with or without detrusor contractions. The right
diagnosis enables starting the appropriate treatment.
Patients with incontinence without DO had less favor-
able treatment results than those with DO [2].
There are a few tests, apart from urodynamic investi-
gations, to confirm DO. Bright et al. [20] reported that
bladder wall thickness could be used for detecting DO.
Hubeaux et al. [21] mentioned that heart rate variability
can predict DO. Last years’ study indicated that a measure











Girls n (% of entire group) 10 (41.67) 4 (16.67) 8 (66.67) 4 (16) 10 (41.67)
Boys n (% of entire group) 4 (16.66) 0 (0) 4 (16.67) 2 (8) 2 (8)
Total n (% of entire group) 14 (58.33) 4 (16.67) 12 (50) 6 (25) 12 (50)














Pdet urg (cm H2O) 30 (7–63)
CC (ml) 109 (50–240)
Compliance (ml/cm H2O) 11.5 (0.6–27.8)
Max p det (cm H2O) 60 (11–149)
Uroflowmetry
Tmax flow (s) 4.63 (1–12) 5 (1.67–12) 7 (4–12) 0.005 \0.01 \0.01
Delay time (s) 4 (1–17.67) 3 (1–26) 2 (1–3) 0.331 \0.01 \0.01
Flow time (s) 11.5 (5–38) 12 (6.33–38) 17 (10–38) 0.004 \0.01 0.001
Voiding time (s) 12.75 (5–41) 13.5 (6.33–41) 19.5 (11–41) 0.002 \0.01 \0.01
Max flow rate (ml/s) 22.3 (8.04–46.70) 23.54 (10.73–41) 22.9 (13.3–41) 0.881 0.852 0.565
Av flow rate (ml/s) 11.9 (6.1–22.1) 12.52 (5.2–19.8) 12.8 (6.7–25.3) 0.232 0.543 0.465
Voided volume (ml) 134.34 (44.5–456) 188 (45.6–465) 219.5 (104–455) 0.008 \0.01 0.004
RU (ml) 0 (0–35) 0 (0–20) 0 (0–3) 0.173 0.215 0.289
Significant value p\ 0.05
A before, B during anticholinergic treatment, C comparison among studied group and between patients and healthy controls, Pdet urg detrusor
pressure at urgency, Max p det maximum detrusor pressure, Tmax flow time to maximum flow, Max flow rate maximum flow rate, Av flow rate
average flow rate, RU residual urine
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of urinary NGF levels was a very simple procedure for
detecting/confirming DO [5, 6, 15–17, 19]. Our results are
compared with those of other authors and suggest that
urinary NGF levels are associated with DO [5, 16, 19]. The
cut-off value of NGF/cr. was 5.8 pg/mg and the number of
false results (negative––2, positive––3) was quite low.
Assessment of uNGF levels may be valuable in such
abnormalities as vesicoureteral reflux. So far, urodynamic
investigation is a gold standard in detecting DO in these
patients. It enables deciding on the appropriate treatment
(surgical or conservative therapy). The question is whether
NGF/cr. could be useful for detecting DO in patients who
were treated for OAB in the past and when deterioration
appeared after a temporary improvement. It might help to
start the appropriate therapy immediately without urody-
namic procedures.
The next very important problem is how long pharma-
cological therapy should last. It seems that bladder function
returns to normal after a few weeks of treatment.
According to Liu et al. [17] 4 weeks of therapy is an
appropriate amount of time for making the decision whe-
ther therapy is adequate or not (responders or not
responders).
Yokoyama [22] (based on an adult population) and
Korzeniecka-Kozerska et al. [23] concluded that uNGF
level was elevated in patients with neurogenic bladder
independent of urodynamic findings and correlated with
the final pressure in the bladder. Elevated levels of urinary
NGF in DO patients may suggest that DO might be caused
by neurogenic dysfunction. On the other hand Yokoyama
[22] suggested that NGF levels were increased in patients
who responded to resiniferatoxin (RTx) treatment. In
patients with DO, it helps to change and/or choose the
appropriate treatment. Our findings, like others [11, 17],
show that uNGF levels decreased after anticholinergic
treatment, and can suggest that DO is caused by acetyl-
choline release on the activation of muscarinic receptors in
the bladder afferent pathways. This explains why antimu-
scarinic treatment is the most useful in young patients.
Another study by Vijaya et al. [24] showed that urinary
NGF was responsive to antibiotic therapy and women with
refractory overactive bladder and elevated NGF may ben-
efit from antibiotic treatment. We did not confirm this
observation because our patients were not diagnosed with
median=8.96; Chi2  =17.167,df=2 p=0.0002






























Fig. 1 Urinary NGF/cr. median
levels in patients with DO
(A before treatment; B after
treatment) and comparison

















AUC=0.995; SE=0.007; CI (0.982-1.0)
Fig. 2 Receiver-operating characteristic curve shows sensitivity and
specificity for uNGF level
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UTIs during NGF estimation, and moreover part of them
received antibacterial prophylactic treatment and in spite of
this we observed elevated urinary NGF level before and
normalized after anticholinergic treatment.
Voiding diaries, visual analog scale and so on are good
noninvasive methods for assessment of urgency, but all of
them have some limitations [25]. They can not be used in
infants and toddlers when the diagnosis of lower urinary
tract dysfunctions is very important in many congenital
abnormalities. Average daily frequency and incontinence
episodes are good methods for estimating response to DO
treatment but can be used in older children only. Addi-
tionally, patients with large bladder capacity, especially
without incontinence, can have DO which could not be
diagnosed based only on clinical symptoms. Thus, uNGF
level is a good way to confirm the effectiveness of treatment
in all age groups and allows for a more objective diagnosis
compared with that based on subjective symptoms only. Liu
et al. [17] and Finney et al. [26] claimed that antimuscari-
nics could be used for OB treatment during the storage
phase without reducing detrusor pressure or urine flow
during the voiding phase. Our current studies confirmed this
effect (no differences between maximum flow rate before
and after treatment) as well as correlations between uNGF
level and bladder wall compliance and detrusor pressure
during the voiding phase before treatment.
Our findings need to be confirmed in a further larger
study to find out whether uNGF might be a DO predictor in
young patients with various clinical manifestations.
Our study had several limitations. First, the study group
was quite small. Second, the uNGF level was not assessed
after treatment completion. We will try to continue the study,
however, it is usually difficult to follow up with young
patients.
In summary, the results of this current study showed that
uNGF levels are higher in patients with DO when compared
with the reference group, and decreased after anticholiner-
gic treatment and correlated with urodynamic findings.
Further studies are necessary to answer the question
whether uNGF could be used for DO detection in children
and adolescents. Measurement of uNGF level is a simple,
noninvasive procedure for choosing therapy in patients
with DO in various clinical conditions.
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